

01-18-02

01/16/02  
J1057 U.S.  
PTO

**UTILITY**  
**PATENT APPLICATION**  
**TRANSMITTAL**

(only for new nonprovisional applications under 37 CFR 1.53(b))

Atty. Docket No.

ORT-1417

First Inventor

FOURIE, Anne M.

Title

Aggrecanase-1 and -2 peptide substrates and methods

Express Mail Label No.

EL568230589US

**APPLICATION ELEMENTS**

See MPEP Chapter 600 concerning utility patent application contents.

1.  Fee Transmittal Form (e.g., PTO/SB/17)  
*(submit an original and a duplicate for fee processing)*
2.  Applicant claims small entity status.
3.  Specification [Total Pages 25]  
*(Preferred arrangement set forth below)*
  - Descriptive Title of the Invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings *(if filed)*
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4.  Drawing(s)(35 USC 113) [Total Sheets 5]
5. Oath or Declaration [Total Pages 3]
  - a.  Unexecuted (original or copy)
  - b.  Copy from a prior application (37 CFR 1.63(d))  
*(for continuation/divisional with Box 18 completed)*

i.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6.  Application Data Sheet. See 37 CFR 1.76

18.  If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation     Divisional     Continuation-in-Part (CIP) of prior application No.: , filed

Prior application information: Examiner Group Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

 Customer Number or Bar Code Label 000027777 or  Correspondence Address below

Name: Philip S. Johnson, Esq.  
 Address: Johnson & Johnson  
           One Johnson & Johnson Plaza  
           New Brunswick, NJ 08933-7003 USA

## 20. TELEPHONE CONTACT

Please direct all telephone calls or telefaxes to Myra H. McCormack at:

Telephone: (732) 524-6932    Fax: (732) 524-2808

## 21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	Myra H. McCormack	Reg. No. 36,602
SIGNATURE	<i>Myra H. McCormack</i>	

ADDRESS TO: Commissioner for Patents  
Box Patent Application  
Washington, DC 202317.  CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

a.  Computer Readable Form (CRF)b.  Specification Sequence Listing on:i.  CD-ROM or CD-R (2 copies); orii.  paper (21 pages)c.  Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9.  Assignment Papers (cover sheet & document(s))10.  37 CFR 3.73(b) Statement  Power of Attorney  
*(when there is an assignee)*11.  English Translation Document *(if applicable)*12.  Information Disclosure Statement  
(IDS)/PTO-1449  Copies of IDS Citations13.  Preliminary Amendment14.  Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*15.  Certified Copy of Priority Document(s)  
*(if foreign priority is claimed)*16.  Request and Certifications under 35 U.S.C. 122  
(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.17.  Otherjic997 U.S. PTO  
01/16/02

01/16/02

**FEE TRANSMITTAL**


Complete if Known	
Application Number	
Filing Date	January 16, 2001
First Named Inventor	FOURIE, Anne M.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-1417

**FEE CALCULATION****CLAIMS AS FILED**

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE \$710.00
TOTAL CLAIMS	19 - 20 =	0	x 18.00	\$ 0.00
INDEPENDENT CLAIMS	4 - 3 =	1	x 80.00	\$ 80.00
MULTIPLE DEPENDENT CLAIMS	<input type="checkbox"/>	N/A	\$270.00	
			TOTAL FEES	\$ 790.00

**METHOD OF PAYMENT**

- Please charge Deposit Account No. 10-0750/ORT-1417/MHM in the amount of \$790.00.  
Three copies of this sheet are enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/ORT-1417/MHM. Three copies of this sheet are enclosed.

<b>SUBMITTED BY:</b>		Complete (if applicable)
Typed or Printed Name	Myra H. McCormack	Reg. No. 36,602
Signature		Date: January 16, 2002 <b>Deposit Account No. 10-0750</b>

IN THE UNITED STATES  
PATENT AND TRADEMARK OFFICE

Applicant: Anne Fourie et al

For : AGGRECANASE -2 AND -2 PEPTIDE SUBSTRATES AND METHODS

Express Mail Certificate

"Express Mail" mailing number: EL568230589US

Date of Deposit: January 16, 2002

I hereby certify that this complete application, including 25 specification pages, 19 claims, informal drawings and an unexecuted Declaration and Power of Attorney, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

A Combined Declaration and Power of Attorney will be submitted to the United States Patent and Trademark Office upon receipt of the U.S. Serial Number for this patent application.

Karen Hall-Morgan

(Typed or printed name of person mailing paper or fee)

Karen Hall-Morgan  
(Signature of person mailing paper or fee)